
A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
This International Women's Day, the Dermatology Times® team is taking the time to spotlight women in the dermatology field.






